Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Lymphoma × venetoclax × Clear all

Phase

Status

Recruiting 9 Completed 6 Withdrawn 1 Unknown 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 33 Leukemia, Lymphocytic, Chronic, B-Cell 24 Myelodysplastic Syndromes 12 Leukemia, Myelomonocytic, Chronic 8 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Neoplasms 6 Recurrence 5 Lymphoma, Mantle-Cell 5 Burkitt Lymphoma 5 Myeloproliferative Disorders 4 Multiple Myeloma 4 Lymphoma, Non-Hodgkin 4 Lymphoma, B-Cell 4 Leukemia, B-Cell 4 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Large B-Cell, Diffuse 3 Lymphoma, Follicular 3 Lymphoma, B-Cell, Marginal Zone 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3 Leukemia 3 Primary Myelofibrosis 2 Leukemia, Biphenotypic, Acute 2 Waldenstrom Macroglobulinemia 1 Thrombocytosis 1 Thrombocythemia, Essential 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pathologic Complete Response 1 Neoplasms, Plasma Cell 1 Neoplasm, Residual 1

Interventions

Cyclophosphamide 24 Rituximab 18 fludarabine 13 Biopsy 13 Specimen Handling 12 Prednisone 11 Magnetic Resonance Spectroscopy 11 Doxorubicin 11 Vincristine 9 fludarabine phosphate 8 Bendamustine Hydrochloride 8 Tacrolimus 6 Melphalan 6 Etoposide 6 Whole-Body Irradiation 5 Mycophenolic Acid 5 trametinib 4 Peripheral Blood Stem Cell Transplantation 4 Nuclear Medicine Department, Hospital 4 Methods 4 Lenalidomide 4 Cytarabine 4 Busulfan 4 AP 1903 reagent 4 pembrolizumab 3 copanlisib 3 acalabrutinib 3 X-Rays 3 Radiotherapy 3 Prednisolone 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05951959 2025-10-21

TrAVeRse

AstraZeneca

Phase 2 Active not recruiting

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡